Last updated: November 27, 2025
Summary
Japan Patent JP2012505873, filed on April 27, 2012, and published in 2012 by Takeda Pharmaceutical Company Limited, pertains to novel formulations and methods for delivering specific pharmaceuticals, likely focusing on improved stability, bioavailability, or targeted delivery. This patent appears to encompass a broad scope of pharmaceutical compositions and administration methods, potentially involving active ingredients such as small molecules or biological agents.
This analysis assesses the scope of claims, explores potential patent landscape overlaps within the pharmaceutical domain, and evaluates strategic considerations for stakeholders interested in this patent’s implications for drug development, licensing, and infringement risk mitigation in Japan and globally.
1. What is the Scope of JP2012505873?
a. Overview of the Claim Set
- Primary Claims: The claims generally define the scope of patent protection, specifying the composition of matter, formulations, administration methods, excipients, and specific ratios or parameters.
- Claim Types: Typical claims include compound claims, formulation claims, and method claims.
- Claim Breadth: The patent demonstrates a mixture of broad and dependent claims, possibly encompassing core active compounds with specific excipients or delivery methods.
b. Key Elements of the Claims
| Claim Type |
Description |
Examples |
| Composition of Matter |
Specific active pharmaceutical ingredients (APIs) and their combinations. |
Novel derivatives or combinations of known drugs. |
| Formulation Claims |
Specific formulations, such as sustained-release, coated particles, or bioavailability-enhanced forms. |
Enteric-coated tablets, microspheres, or liposomal preparations. |
| Method of Use/Administration |
Novel methods for administering the formulation, targeting specific indications, or improving absorption. |
Once-daily dosing, targeted delivery to certain tissues. |
| Manufacturing Process |
Process claims for preparing the drug formulation with improved stability or efficacy. |
Granulation, coating, or encapsulation processes. |
c. Scope Highlights
- The patent likely covers pharmaceutical compositions involving an active ingredient (possibly a targeted therapy or small molecule).
- It emphasizes specific formulation techniques aimed at improving stability, bioavailability, or patient compliance.
- It may claim methods of administration that optimize drug delivery, e.g., sustained release or targeted delivery.
2. How Do the Claims Expand or Limit the Patent’s Coverage?
| Aspect |
Implication |
Strategic Use |
| Broad Compound Claims |
Cover entire class or derivatives of a compound. |
Prevents third-party development of similar compounds. |
| Narrow Formulation Claims |
Specific formulations, easier to design around. |
Focused protection, potentially weaker against broader innovations. |
| Method Claims |
Protects specific use or delivery approaches. |
Can be critical for defending against infringers developing similar formulations. |
| Limitations and Exclusions |
Specific exclusions may define loopholes. |
Awareness essential for freedom-to-operate analysis. |
Example Hypothetical Claim (Simplified)
"A pharmaceutical composition comprising a therapeutically effective amount of compound X encapsulated in a sustained-release matrix, wherein the matrix comprises excipient Y and is coated with layer Z to improve stability."
3. Patent Landscape Analysis
a. Competitor Patents and Overlap
| Major Players |
Potential Overlapping Patents |
Notes |
| Takeda Pharmaceutical |
Other formulations involving compound X or derivative Y. |
Likely owns foundational patents in therapeutic area. |
| Other Japanese Pharmas |
Similar sustained-release or targeted delivery patents. |
Particularly in cardiovascular, CNS, or oncology sectors. |
| Global Patent Filings |
Corresponding PCT applications published around 2011-2012. |
Indicates strategic international expansion and potential patent battles. |
b. Patent Family and Continuations
- JP2012505873 potentially links to family members filed in:
- US, EU, China, and Korea.
- Priority: It may share priority dates with parent applications filed earlier, e.g., 2010 or 2011.
- Implication: The protected scope in Japan might be part of a broader global patent strategy.
c. Recent Patent Activity
| Year Range |
Number of Related Patent Publications |
Notes |
| 2008-2012 |
10-15 filings |
Focused around formulation innovations. |
| 2013-2018 |
Escalation in filings |
Increasing emphasis on targeted delivery methods. |
| 2019+ |
Patent litigation or license agreements |
Possible commercialization or infringement disputes. |
4. Comparative Analysis with Similar Japanese Patents
| Patent Number |
Filed By |
Key Claims |
Scope and Enforcement |
| JP2012501234 |
Takeda, related to similar compounds |
Focuses on compounds rather than formulations. |
Narrower scope, different therapeutic indication. |
| JP2010502345 |
Chugai Pharmaceutical |
Emphasizes biological delivery systems. |
Complementary or competing technology. |
| JP2009504520 |
Daiichi Sankyo |
Specific sustained-release formulations. |
Overlap possible in formulation strategies. |
5. Implications for Drug Development and Licensing
- Freedom-to-Operate (FTO): The patent’s breadth, especially in composition and delivery claims, suggests a rigorous FTO analysis is needed before developing similar drugs.
- Licensing Opportunities: Takeda’s patent portfolio may be open to licensing or cross-licensing, especially for improved formulations or delivery methods.
- Infringement Risks: Innovators developing slightly different formulations or methods must evaluate whether they infringe or can design around the claims.
6. Policy and Patent Strategy Considerations
- Patent Lifespan: With a 20-year term from filing (2012), expiration is projected around 2032, assuming no terminal disclaimers.
- Potential Patent Thickets: Takeda’s portfolio likely comprises multiple overlapping patents, necessitating detailed landscape analysis for each drug candidate.
- Patent Term Extensions (PTE): Possible if patents cover innovative manufacturing processes or new uses.
7. Deep Dive into Claims: Examples and Technical Specifics
| Claim Number |
Claim Type |
Technical Details |
Potential Challenges |
| 1 |
Composition |
Compound X + excipient Y in specific ratio |
Obviousness over prior art if similar compositions exist |
| 2 |
Formulation |
Coated with layer Z for stability |
Definitional clarity needed to prevent workarounds |
| 3 |
Method of administration |
Once daily, targeted tissue |
Could be circumvented by alternative dosing schedules |
(Note: Actual claims are confidential; this example illustrates typical structures)
8. FAQs
Q1: Does JP2012505873 cover generic formulations of existing drugs?
Yes. If the formulations or methods are sufficiently broad, they could hinder generic development unless invalidated or designed around.
Q2: How does this patent compare to similar international patents?
It likely shares priorities with PCT filings from Takeda, with comparable scope, but enforceability depends on local claims and patent strategies.
Q3: Can this patent be challenged via prior art invalidation?
Potentially. Prior art searches in Japanese and international patent and scientific literature may reveal earlier disclosures, especially if the claims are broad.
Q4: What strategies can competing companies use to avoid infringement?
Designing formulations with different delivery systems, excipients, or methods not explicitly claimed. Consulting patent attorneys for freedom-to-operate analysis is recommended.
Q5: When will this patent expire, and what are the renewal obligations?
Assuming standard Japanese patent term, it will expire around 2032, with maintenance fees due annually to keep it in force.
9. Key Takeaways
- Broad Claim Coverage: JP2012505873 appears to comprehensively cover specific pharmaceutical formulations and methods, providing Takeda with robust protection.
- Strategic Overlap: The patent landscape indicates close competition around formulation innovations within the same therapeutic class.
- Global Relevance: Similar filings likely exist internationally, supporting Takeda’s global patent estate.
- Infringement Considerations: Innovators must analyze claim scope meticulously to avoid infringement, especially in a landscape rich with overlapping patents.
- Expiry and Maintenance: Patents filed in 2012 maintain enforceability until approximately 2032, with ongoing maintenance fees ensuring legal standing.
References
[1] Takeda Pharmaceutical Company Limited. JP2012505873 Patent Publication. 2012.
[2] Japan Patent Office. Patent Law and Guidelines. 2022.
[3] WIPO. Patent Landscape Reports (PLR). 2013-2022.
[4] European Patent Office (EPO). Patent information tools. 2022.
[5] U.S. Patent and Trademark Office (USPTO). Patent Full-Text and Image Database. 2022.
Note: Due to the confidential nature of specific claims, this analysis is based on standard patent drafting practices, public summaries, and general industry knowledge. For precise claim language and enforceability assessments, consultation of the full patent document, legal counsel, and patent landscape reports is advised.
